Approval · Notice of Compliance 29299 · 2022
ELONOX: Notice of Compliance 29299
Issued October 26, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29299
- Date
- October 26, 2022
- Company
- Fresenius Kabi Canada LtdToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
- Canadian reference product
- LOVENOX / LOVENOX HP
Products in this notice
Medicinal ingredients
- ENOXAPARIN SODIUM 30 MG per 0.3ML
- ENOXAPARIN SODIUM 40 MG per 0.4ML
- ENOXAPARIN SODIUM 60 MG per 0.6ML
- ENOXAPARIN SODIUM 80 MG per 0.8ML
- ENOXAPARIN SODIUM 100 MG per ML
- ENOXAPARIN SODIUM 150 MG per ML